|
|
2.
|
Nivolumab or capecitabine or combination therapy as adjuvant therapy for triple negative breast cancer (TNBC) with residual disease following neoadjuvant chemotherapy: the OXEL study. MedStar authors:
- Dilawari, Asma
- Gallagher, Christopher
- Khoury, Katia
- Lynce, Filipa
- Swain, Sandra M
Year: 2018
Department: - MedStar Georgetown University Hospital Residents
All authors: - Khoury K, Isaacs C, Gatti-Mays M, Donahue R, Schlom J, Wang H, Gallagher C, Graham D, Warren R, Dilawari A, Swain S, Pohlmann P, Lynce F.
|
